BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Elacestrant readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Elacestrant\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06691035-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Elacestrant: Phase 1 readout est. (NCT06691035)
DESCRIPTION:Elacestrant\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressin
 g Metastatic Breast Cancer\nEstimated primary completion: November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/elacestrant#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06691035
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05596409-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Elacestrant: Phase 2 readout est. (NCT05596409)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Rec
 eptor Positive\, HER-2 Negative Metastatic Breast Cancer Study\nEstimated 
 primary completion: November 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/elacestrant#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05596409
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05982093-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Elacestrant: Phase 2 readout est. (NCT05982093)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Elacestrant With/Without Triptorelin in Premenopausal Women With Lumi
 nal Breast Cancer\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/elacestrant#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05982093
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Elacestrant: Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Elacestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elaces
 trant In Various Combination In Participants With Metastatic Breast Cancer
 \nEstimated primary completion: 27 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/elacestrant#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159451-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07159451)
DESCRIPTION:Elacestrant\, phase 2\, Breast Cancer.\nStudy: A Short-term Pre
 operative\, Evaluating Activity and Safety of Elacestrant Monotherapy as C
 ompared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Pr
 emenopausal Patients With Stage I-II ER+/HER2- Breast Cancer\nEstimated pr
 imary completion: 29 January 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/elacestrant#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07159451
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005882-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07005882)
DESCRIPTION:Elacestrant\, phase 2\, Breast Cancer.\nStudy: Hormonal Recepto
 r (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preopera
 tive ELacestrant and PULSAR Radiotherapy\nEstimated primary completion: 1 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elacestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7005882
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07467772-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07467772)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Ph 2 Elacestrant in ER Positive Uterine Sarcomas\nEstimated primary c
 ompletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /elacestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07467772
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05386108-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Elacestrant: Phase 1/2 readout est. (NCT05386108)
DESCRIPTION:Elacestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Study of Abemaciclib and Elacestrant in Participants With Brain Met
 astasis Due to ER+/HER-2- Breast Cancer\nEstimated primary completion: Aug
 ust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elacestrant
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT053
 86108
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06923527-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Elacestrant: Phase 2 readout est. (NCT06923527)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Circulating Tumor DNA\nEstimated primary completion: September 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/elacestrant#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06923527
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06638307-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20271024
DTEND;VALUE=DATE:20271025
SUMMARY:Elacestrant: Phase 1 readout est. (NCT06638307)
DESCRIPTION:Elacestrant\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A First-in-Human Study of MEN2312 in Adults With Advanced Breast Canc
 er\nEstimated primary completion: 24 October 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/elacestrant#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06638307
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05573126-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Elacestrant: Phase 1/2 readout est. (NCT05573126)
DESCRIPTION:Elacestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combinatio
 n in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer\nEs
 timated primary completion: February 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/elacestrant#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05573126
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07198724-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Elacestrant: Phase 1/2 readout est. (NCT07198724)
DESCRIPTION:Elacestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deru
 xtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-
 low or HER2-ultralow Metastatic Breast Cancer\nEstimated primary completio
 n: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elace
 strant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07198724
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06062498-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Elacestrant: Phase 2 readout est. (NCT06062498)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With E
 Rpositive/HER2-negative Advanced or Metastatic Breast Cancer\nEstimated pr
 imary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/elacestrant#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06062498
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07766018-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07766018)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Me
 tastatic Breast Cancer\nEstimated primary completion: October 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/elacestrant#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07766018
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07209449-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07209449)
DESCRIPTION:Elacestrant\, phase 2.\nStudy: A Study of Elacestrant Alone or 
 in Combination With Abemaciclib in People With Endometrial Cancer\nEstimat
 ed primary completion: 1 October 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/elacestrant#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07209449
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06075953-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Elacestrant: Phase 2 readout est. (NCT06075953)
DESCRIPTION:Elacestrant\, phase 2.\nStudy: DCIS: RECAST Trial Ductal Carcin
 oma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability 
 as Treatment\nEstimated primary completion: November 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/elacestrant#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06075953
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07395336-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07395336)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Met
 astatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)\nEstimated prim
 ary completion: December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/elacestrant#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07395336
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634601-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20281218
DTEND;VALUE=DATE:20281219
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07634601)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Elacestrant With Everolimus for the Treatment of Recurrent Advanced o
 r Metastatic ER-Positive Endometrial Cancer\nEstimated primary completion:
  18 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/el
 acestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07634601
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06201234-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Elacestrant: Phase 2 readout est. (NCT06201234)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-
 inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer\nE
 stimated primary completion: 31 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/elacestrant#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06201234
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612215-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Elacestrant: Phase 1/2 readout est. (NCT07612215)
DESCRIPTION:Elacestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Elacestrant in Advanced Triple Positive Breast Cancer\nEstimated pr
 imary completion: May 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/elacestrant#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07612215
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492616-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Elacestrant: Phase 3 readout est. (NCT06492616)
DESCRIPTION:Elacestrant\, phase 3\, Breast Cancer.\nStudy: A Study of Elace
 strant Versus Standard Endocrine Therapy in Women and Men With ER+\,HER2-\
 , Early Breast Cancer With High Risk of Recurrence\nEstimated primary comp
 letion: August 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 elacestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06492616
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120283-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Elacestrant: Phase 1 readout est. (NCT06120283)
DESCRIPTION:Elacestrant\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: BGB-43395 Alone or as Part of Combination Therapies in Participants W
 ith Breast Cancer and Other Advanced Solid Tumors\nEstimated primary compl
 etion: December 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /elacestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06120283
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222215-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07222215)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in 
 ER+ Breast Cancer (CAPELA)\nEstimated primary completion: 1 December 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/elacestrant#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07222215
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07753954-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20310819
DTEND;VALUE=DATE:20310820
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07753954)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Medical Imaging to Re-evaluate Elacestrant Clinical Usage\nEstimated 
 primary completion: 19 August 2031. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/elacestrant#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07753954
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05512364-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20321101
DTEND;VALUE=DATE:20321102
SUMMARY:Elacestrant: Phase 3 readout est. (NCT05512364)
DESCRIPTION:Elacestrant\, phase 3\, Breast Cancer.\nStudy: Elacestrant for 
 Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
 \nEstimated primary completion: 1 November 2032. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/elacestrant#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05512364
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07242352-9037@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20330930
DTEND;VALUE=DATE:20331001
SUMMARY:Elacestrant: Phase 3 readout est. (NCT07242352)
DESCRIPTION:Elacestrant\, phase 3\, Breast Cancer.\nStudy: Marker - Adjuste
 d Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment
  in Genomically and/or Clinically High-risk ER+/HER2- eBC\nEstimated prima
 ry completion: 30 September 2033. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/elacestrant#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07242352
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
